• Fri, September 9, 2022
Chris Shibutani Maintained (AMLX) at Hold with Increased Target to $40 on, Sep 9th, 2022
Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Hold with Increased Target from $22 to $40 on, Sep 9th, 2022.
Chris has made no other calls on AMLX in the last 4 months.
There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 0 agree with Chris's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Chris
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $50 on, Thursday, September 8th, 2022
- Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $48 on, Thursday, September 8th, 2022